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1. Introduction
The date of adenoviruses’ discovery is considered to be in 1953, when a cytopathogenic agent 
was identified during the long-term cultivation of the tissues of the tonsils and adenoids 
after operations in children with Rowe and coworkers [1]. This determined the name of the 
viruses (adenoid degeneration viruses) and outlined their basic ecology associated with 
asymptomatic persistence in the lymphoid tissue. Soon, adenoviruses were isolated from 
materials obtained from patients with acute respiratory diseases accompanied by conjunc-
tivitis [2]. In 1954, Huebner received the new data indicating that similar viruses are also 
found in the secretes of patients with acute pharyngitis and conjunctivitis, and therefore 
they were called “adenoid-pharyngeal-conjunctival viruses” [1]. In the same year, another 
group of researchers, when studying the etiology of acute respiratory infections and atypical 
pneumonia, isolated a previously unknown virus from the US Army recruits, named RI-67. It 
further proved the adenoviruses’ identity with the adenoid-pharyngeal-conjunctival virus [3]. 
In subsequent years, such viruses were isolated from patients during outbreaks of epidemic 
keratoconjunctivitis, although as an independent disease, it was described in the 20s of the 
twentieth century.
Adenoviruses are the first respiratory viruses that were isolated on tissue culture. The oppor-
tunity to grow up in vitro on synthetic media of various cells of organs and tissues of humans 
and animals, as well as the ability of viruses to multiply on sensitive cells to cause a cytopathic 
effect opened up broad prospects for the development of virology. By 1956, a large number 
of biologically similar but antigenically distinct strains of viruses were identified, which were 
decided to have a group name of adenoviruses [4]. Not less than 120 viruses that infect mam-
mals, birds, reptiles, amphibians, and fish are described in the Adenoviridae family. Further 
study of adenoviruses, the discovery of their new serotypes made it possible to establish that 
this viruses cause not only respiratory diseases but also diarrhea, mesadenitis, hemorrhagic 
cystitis, and other pathological conditions. Only in humans, over 50 adenoviral serotypes are 
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known which cause a wide range of illnesses, from mild respiratory infections in young chil-
dren to life-threatening multi-organ disease in immunocompromised people.
2. Adenoviruses’ nomenclature
This family includes two genera designated based on genetic criteria (Atadenovirus and 
Siadenovirus) as well as three genera, in which adenoviruses are combined according to the 
type of host (Aviadenovirus, Ichtadenovirus, and Mastadenovirus) (https://talk.ictvonline.org/
taxonomy).
Genus Atadenovirus presents the newly formed genus which combines adenoviruses with a 
high relative content of AT-pairs in genomic DNA. This genus includes also adenoviruses of 
snakes, possums, calves, chameleon, ducks, and lizard.
Genus Siadenovirus combines adenoviruses containing at the 5′ end which contains a gene of 
an enzyme sialidase that cuts off sialic acid residues from the surface glycoproteins of the host 
cells. These adenoviruses infect frogs and birds.
Genus Aviadenovirus includes adenoviruses of turkeys, quail, chickens, and a number of other 
birds. The type species causes the death of embryos and respiratory disease in quails and 
chickens. Other members of this genus are pathogens of the egg drop syndrome, hemorrhagic 
enteritis, and hepatitis.
Genus Ichtadenovirus has the only characterized representative which infects white sturgeon—
Sturgeon ichtadenovirus A.
Genus Mastadenovirus includes various viruses of mammals: viruses of cows, sheep, deer, 
pigs, dogs along with all human adenoviruses.
In humans, 57 adenoviruses are known, which are divided into 7 groups (A–G).
3. Structure
Adenoviruses are non-enveloped viruses, 80–90 nm in diameter. The icosahedral capsid of 
adenoviruses consists of hexones carrying group-specific and type-specific antigens and pen-
tones containing mainly group-specific antigens at each apex. From each pentone there is a 
fiber with a head at the end (Figure 1).
Structural proteins of adenoviruses are designated by Roman numerals in descending order of 
molecular weight. The adenovirus capsid consists of seven structural proteins; three major cap-
sid proteins hexon, fiber, and penton; and four minor proteins protein IIIa (pIIIa), VI, VIII, and 
protein IX [5]. Fibers provide binding to cellular receptors and participate in the discrimination 
of infected cells, causing inhibition of the synthesis of cellular macromolecules [6]. Soluble 
 proteins of pentone cause a cytopathic effect similar to the action of infectious adenoviruses, 
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but it manifests itself much faster (after 4–6 h). The pathogenetic significance of hexons is con-
firmed by the fact that antibodies against their epitopes demonstrated a neutralizing effect. 
They may be involved in the development of receptor-dependent endocytosis initiated by 
fibers, the main target for neutralizing antibodies [7].
A feature of adenoviral DNA is the presence of a terminal protein (TP), which is covalently 
linked to the 5′ end of each of the DNA strands. One of the possible functions of TP is the DNA 
attachment to the nuclear matrix after viral genome has entered the nucleus. Due to the interac-
tion of TP, DNA is retained in the form of a ring structure, thus increasing the efficiency of 
transfection of adenoviral DNA isolated from virions [8]. The size of DNA is (20–25) 103 kDa, 
which corresponds to approximately 36,000 base pairs. This would be enough for about a dozen 
medium-sized proteins, but the information capacity of DNA is much more: adenoviruses syn-
thesize about 40 proteins. This is achieved by reading information from both DNA strands and 
alternative splicing, which provides several types of mRNA based on the primary transcript 
of one gene. The 13 proteins are included in the mature virion, the rest belong to nonstructural 
components, functioning at the stage of intracellular reproduction of the virus [9].
4. Antigenic structure
Antigenic structure of Mastadenovirus is represented by three soluble antigens: the hexone 
A-antigen is common for all serotypes; pentone antigen (B-antigen) is a toxic antigen, it inhib-
its the action of interferon and increases the severity of associated respiratory infections; and 
fibril C-antigen is a type-specific which promotes the adsorption of adenoviruses on monkey 
or rat erythrocytes and causes their agglutination. Manifest forms of the disease cause epi-
demic serotypes (3, 4, 7, 14, 21) of subgroups B and E. Serotypes 1, 2, 5, and 6 subgroups C 
cause a latent current, contributing to the formation of chronic tonsillitis and adenoiditis. 
Clinical forms of adenovirus infection presented in Table 1.
Figure 1. Adenovirus structure (from Linda Stannard, of the Department of Medical Microbiology, University of Cape 
Town).
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The WHO have reported that data on the incidence and ramp prevalence of adenoviral infec-
tions are not exact, since in many cases, adenoviruses cause mild forms and therefore remain 
unregistered, according to general practitioners [16]. However, in recent years, adenoviruses 
caused widespread outbreaks in Asia [17–19] in which adenoviral infection was accompanied 
by the development of acute respiratory distress syndrome (ARDS) in Malaysia [18], China 
[16, 19], and South Korea [19].
5. Transmission
The source of infection is a sick person in the acute stage of the disease, convalescent, or a 
virus carrier. Pathogens are secreted with nasopharyngeal secretions, sputum, conjunctival 
discharge, feces, and urine (mainly in individuals with immunosuppression). The timing of 
isolation of pathogens from the upper respiratory tract reaches the 25th day of illness onset 
and more than 1.5 months with feces. Adenoviral infections are transmitted by airborne, 
introducing the virus to the conjunctiva and possibly by the fecal-oral route, thus affecting 
not only the respiratory tract but also other organs. The widespread disease is 5–10% of all 
viral diseases. Incidence is recorded throughout the year with a rise in the cold season. Both 
sporadic cases and epidemic outbreaks are observed. The most susceptible to infection are 
children from 6 months to 5 years, as well as military personnel. Particularly it has a high 
incidence in the newly formed groups of children and adults (in the first 2–3 months). In 95% 
of the adult population, antibodies to the most common serotypes of the virus can be detected 
in the serum [20].
6. Reproduction
The deproteinization of viruses entered the cell starts in the cytoplasm and ends in the nucleus, 
where DNA is released with a terminal protein attached to it. Transcription of the genome 
and replication of viral DNA occur in the nucleus with the help of cellular enzymes [21]. First, 
mRNAs are synthesized, which code for the synthesis of virus-specific enzymes and then also 
RNAs that carry information on the synthesis of capsid proteins and strands. The assembly 
Clinical manifestations Serotype Ref.
Acute respiratory diseases 1, 7, 14, 21 [10]
Viral pneumonia 1, 3, 4, 7, 55 [10–12]
Conjunctivitis 3, 7, 8, 10, 14, 19, 37 [13]
Gastroenteritis 9, 11, 31, 40, 41 [9, 14]
Meningoencephalitis 2, 6, 7, 12, 32 [15]
Table 1. Clinical forms of adenovirus infection.
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of virus particles occurs in the nucleus, where crystal-like inclusions are formed. Several hun-
dred viral particles are synthesized in each cell. The release of adenoviruses is accompanied 
by the destruction of the host cell. The cycle of reproduction of adenoviruses in the cell lasts 
14–24 h.
Adenoviruses can multiply in different cells, including airway epithelial cells and lymphocytes. 
Virus-infected cells become targets for immunity effectors. However, adenoviruses impose 
such properties on cells that allow them to avoid destruction or at least reduce this possibility. 
Adenoviruses produce factors that block the synthesis and expression of HLA-I molecules on the 
cell surface and thereby inhibit the presentation of viral antigens attacked by CD8 + T-lymphocytes. 
Cells infected with adenoviruses acquire increased resistance to interferons and TNF-a, a potent 
cytotoxic cytokine. In both cases, adenoviral proteins interfere with molecular mechanisms that 
determine antiviral effects. Among the products of early adenoviral genes are factors that delay 
the development of apoptosis. In general, this reflects a strategy aimed at improving the survival 
of infected cells and creating conditions for viral persistence [22].
7. Pathogenesis
From the pathogenetic point of view, adenoviruses damage the respiratory tract and belong 
to the “respiratory” viruses. However, adenoviruses also can cause lesions of the intestine 
and conjunctiva, as well as the central nervous system, bladder, and genitals. Adenoviruses 
multiply in the mucous membrane with a gradual, consistent involvement in the pathological 
process of the descending parts of the respiratory tract. Reproduction of adenoviruses also 
can occur in the intestinal tissue or lymph nodes which is accompanied by a multiple increase 
in lymph nodes. In addition to local changes, adenoviruses have a general toxic effect which 
appears as a fever and symptoms of general intoxication (weakness, lethargy, loss of appetite, 
headache, and nausea). The ability of adenoviruses to reproduce in the epithelial cells of the 
respiratory tract, conjunctiva, and intestine with the occurrence in some cases of hematog-
enous dissemination creates a wide range of clinical manifestations of this infection, including 
the appearance of generalized lymphadenopathy and widespread exanthema. In addition to 
adenoviruses in the genesis of acute pneumonia, the attachment of a secondary bacterial flora 
is important, which is facilitated by the suppression of the immune system [23–24].
8. Adenoviral latency
The term “adenoviruses” has an ecological coloration, reflecting the tendency to persistence 
in the lymphoid tissue, so that adenoviruses can be isolated from the tonsils, adenoids, appen-
dix, and lymph nodes of practically healthy people.
After acute infections, many serotypes are not eliminated from the body for a long time. Most 
of the latent viruses belong to subgroups B2 and C. They can persist for years in the lymphoid 
tissue of the pharyngeal ring and, apparently, other localizations (e.g., in the mesenteric lymph 
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nodes). Once in the intestine, adenoviruses asymptomatically replicate in the epithelial cells 
and/or Peyer’s patches, periodically evolving from feces.
Latency creates the possibility of endogenous recurrences of acute infection and chronic hyper-
plasia (in fact, chronic inflammation) of infected lymphoid tissue. The possibility of activating 
a viral infection in the tonsils (chronic tonsillitis), mesenteric lymph nodes, and appendix 
is not excluded. Adenoviruses can be activated on the background of immunosuppressive 
therapy in AIDS patients. A number of new serotypes (serotypes 43–47 of subgroup D) were 
first  isolated from AIDS patients (from feces), allowing to believe that a persistent infection 
creates favorable conditions for the evolution of adenoviruses [25].
The mechanism of persistence of adenoviruses in the lymphoid tissue still remains unclear. 
Most likely, this is due to the low content of sensitive (permissive) cells and very slow rep-
lication of the virus in lymphocytes, that is, with severely limited productive infection. It is 
significant that in the experiments of W. Rowe et al., who discovered adenoviruses in 1953, 
it took several weeks for the degeneration of a culture of adenoid tissue associated with the 
reproduction of latent adenoviruses. The possibility of integrative virogeny with partial 
expression of the viral genome is not excluded. In approximately 50% of the tonsils in adults, 
it was possible to detect adenoviral antigens in the absence of an infectious virus.
9. Antiadenovirals
As mentioned above, adenoviruses are unsusceptible to interferons. The acyclic nucleoside phos-
phonates HPMPC (cidofovir) [26] exhibit antiadenoviral activity. However, these substances are 
toxic, so they are applied locally in the form of ointments or by injection directly into the affected 
organ. The target of HPMPC is adenoviral DNA polymerase. The mechanism of the antiviral effect 
of this compound is based on its phosphorylation by cell kinases and in the synthesis of DNA by 
competition with conventional nucleosides. At consecutive inclusion in a thread of two molecules 
of HPMPC, elongation is blocked. The targeted effect of NM on infected cells is provided by a 
higher affinity of HPMPC diphosphate for viral DNA polymerase than for host DNA polymerase.
10. Adenovirus vaccines
Adenovirus infection is perhaps the only respiratory disease other than influenza, against which 
specific prevention methods have been developed. Military contingents in the United States 
since 1971 are vaccinated with live oral adenovirus vaccine against serotypes 7 and 4 which were 
isolated in the 1950s [27]. Live oral adenovirus vaccine has proven to be safe and highly effec-
tive in numerous clinical trials, as well as in clinical observations of acute respiratory infections 
among US military personnel. However, live oral adenoviral vaccine types 4 and 7 are approved 
only for use in military teams for adults 17–50 years old. To avoid the virus being thrown into 
the upper respiratory tract, it is recommended to swallow the tablets whole, without chewing. 
Adenovirus is extremely stable under natural conditions, and there is the possibility of being 
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released into the environment through excreta. Therefore, a vaccine containing live strains of 
adenovirus is not recommended for use in children or the general population. Despite the long-
term stability of the adenovirus genome, which is confirmed by the efficacy of ongoing vaccina-
tion among the US military, random mutations or homologous recombination events, which can 
lead to changes in the antigenicity of adenovirus, are not excluded. In addition, over time, the 
epidemic types of adenovirus have changed, and in recent years, highly pathogenic serotypes 
14 and 55 have been distributed throughout the world. Finally, the circulation of the types of 
adenoviruses can vary geographically; for example, in China, the most common types associated 
with acute respiratory infections (ARI) are types 3, 7, and 55 [28]. Therefore, attention should be 
paid to developing new adenoviral vaccines based on currently circulating adenovirus strains.
11. The mutagenic effect
Representatives of the genus Mastadenovirus served as objects of research in the field of molecu-
lar biology. The intrigue around the pathogenetic function of adenoviruses aggravated after 
their tumorigenic properties, the ability to induce malignant tumors in animals (newborn ham-
sters), was recorded. In 1962, Trentin et al. described the first case of the induction of a malig-
nant tumor in animals by the human pathogenic virus—adenovirus-12, which caused tumors in 
rodents [29]. The oncogenic potential of adenoviruses has served as a stimulus for their careful 
study, which has proved useful for studying the mechanisms of viral infection and molecular 
processes in eukaryotic cells. On the model of adenovirus infection, splicing, adenylation, and 
capturing of matrix RNA, sequence and expression regulation of viral genes, their integration 
with cellular chromosomes, etc. were first studied with human tumors. In a series of works [30, 
31], it was shown that high-oncogenic type 12 adenoviruses and type 18 adenoviruses induce 
chromosomal aberrations in nonpermissive cells for them. The mutagenic effect at the chromo-
somal level has been demonstrated for human type 2 adenoviruses and type 5 in rat cells [32], as 
well as for bovine adenovirus type 3 in Chinese hamster cells [33]. In humans, despite intensive 
research, the association of malignant tumors with adenoviruses has not been identified.
12. The use of adenoviruses as vectors for gene therapy
The promise of using adenoviruses as vectors is due to the fact that a relatively large frag-
ment can be inserted into their linear DNA. With the advent of second-generation vectors, it 
became possible to embed foreign DNA sequences up to 35 kb in the adenovirus genome, while 
maintaining only inverted repeats and packaging site. In addition, adenovirus receptors (e.g., 
termination of the fibers) can be genetically modified in such a way as to increase the tropism of 
the virus in relation to the tumor tissue. As a product of the transgene, which allows to destroy a 
tumor, you can use the herpes virus thymidine kinase (family Herpesviridae) or the chicken ane-
mia virus apoptin (family Circoviridae). In the first case, the patient is prescribed of acyclovir; in 
the second case, the tumor is destroyed as a result of vector-induced apoptosis. Unfortunately, 
genetically engineered constructions based on adenoviral vectors have not yet found clinical 
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application, since due to the use of multiple mechanisms by the virus for penetration into target 
cells, it is not possible to achieve selective delivery of vectors to cancer cells [34, 35].
13. Adenovirus vectors vaccines
Adenovirus vectors first appear in the 1980s. They have received great attention as gene 
delivery systems for vaccine antigens and were extensively tested in several preclinical and 
clinical studies. Adenovirus-based vector vaccines have been developed and are being stud-
ied against a variety of infectious diseases, including influenza, measles, hepatitis B, rabies, 
anthrax, Ebola, severe acute respiratory syndrome (SARS), human immunodeficiency virus 
1 (HIV-1), malaria, tuberculosis [36–40]. A study of an oral tableted vaccine based on a non-
replicative recombinant adenovirus-5 serotype carries DNA that encodes the hemagglutinin 
of A/California/04/2009 (H1N1) pdm with an adjuvant added in the form of double-stranded 
RNA (dsRNA) [41] showed that after a single immunization, significant systemic and local 
immunity occurs. Seroconversions of anti-hemagglutinating antibodies to A/H1N1 pandemic 
influenza viruses were detected in 92% of participants [41].
The advantages of adenoviral vectors are that they efficiently transfer genes to both dividing 
and nondividing cells, do not integrate into the genome, and provide high titers of recom-
binant virus and high expression levels of the introduced genes. Although currently used 
adenoviral vectors may cause nonspecific inflammation and antiviral cellular response [42]; 
this problem still needs to be solved.
14. Conclusions
The study of human and animal adenoviruses allows not only to explore the molecular 
relationship with the host organism but also to solve specific problems of medicine. In the 
practical field, on the one hand, new antiviral vaccines and chemotherapy drugs have been 
developed, implemented, or are awaiting introduction; on the other hand, there is a perspec-
tive on the therapeutic use of viruses, such as oncolytic viruses or viral vectors. These and 
other problems associated with adenoviruses and adenoviral infections will be covered in 
more detail in subsequent chapters of this book.
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